Abstract 2087
Background
The aim of this study was to determine the effect of e-mobile education on the quality of life of women diagnosed with breast cancer who received endocrine hormone therapy.
Methods
The study was conducted as a randomized controlled study between January and July 2018 in the Medical Oncology Outpatient Clinic of a state hospital in the province of Turkey.A total of 64 patients were included in the study according to the inclusion criteria of randomization, split into treatment (n = 31) and control group (n = 33).Data were collected using Patient Introductory Information Form, FACT-ES Quality of Life Scale and NCCN Distress Thermometer.The data were collected twice during the first week of the study and 12th week at the end of the study by face-to-face and/or telephone interviews.Treatment group patients were received information via mobile application for three months during which they were contacted in every 15 days; e-mobile training was provided, including information about breast cancer definition, treatment process, symptoms experienced during endocrine hormone therapy, adequate nutrition, regular physical activity and coping with stress.
Results
The mean total quality of life after e-mobile training to the treatment group was found to be significantly higher than the control group, and the mean distress score was lower than the control group (p < 0.05).For quality of life subscales of patients in the e-mobile training and treatment group; the scores of physical well-being, emotional well-being and endocrine symptoms were found to be significantly higher than the control group (p < 0.05).There was found no difference between the mean scores of social / family well-being subscale scores of the patients in the e-mobile training and treatment group and the control group.Treatment group reported that e-mobile training was “informative and useful a training” (87.1%).
Conclusions
As a result of the study, it has been concluded the quality of life of the patients increased when nurses use the e-mobile training and counseling in order to manage the disease process and symptoms of the women diagnosed with breast cancer and who are receiving endocrine hormone therapy with the help of the developing technologies and using the mobile technologies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3524 - Cabazitaxel For Octogenarian Patients With Metastatic Castration-Resistant Prostate Cancer (MCRPC).
Presenter: Paolo Tralongo
Session: Poster Display session 3
Resources:
Abstract
5637 - External Validation of a Prognostic Score in First-Line Metastastic Castration-Resistant Prostate Cancer (mCRPC)
Presenter: David Lorente
Session: Poster Display session 3
Resources:
Abstract
3228 - Treatment outcomes of 3rd treatment in a real-world metastatic castration resistant prostate cancer (mCRPC) population: results from the Dutch CAPRI-registry
Presenter: Jessica Notohardjo
Session: Poster Display session 3
Resources:
Abstract
4695 - Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion>5%: a propensity score matching analysis from SEER database
Presenter: Junru Chen
Session: Poster Display session 3
Resources:
Abstract
4438 - Multi-institutional evaluation of therapeutic management for oligometastatic cancer prostate recurrence with choline-PET/CT
Presenter: Morgane Guibert-broudic
Session: Poster Display session 3
Resources:
Abstract
4574 - Safety of new androgen receptor inhibitors (ARi) in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): a network meta-analysis of randomized controlled trials (RCT)
Presenter: Amelia Altavilla
Session: Poster Display session 3
Resources:
Abstract
3816 - Real-world use of radium-223 for treatment of metastatic castration resistant-prostate cancer (mCRPC): results from the Dutch CAPRI registry
Presenter: Malou Kuppen
Session: Poster Display session 3
Resources:
Abstract
5180 - A phase 2a study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Daniel Petrylak
Session: Poster Display session 3
Resources:
Abstract
1067 - Adding ADT to PSMA-PET/CT-guided SBRT for oligometastatic prostate cancer improves distant progression-free survival
Presenter: Carole Mercier
Session: Poster Display session 3
Resources:
Abstract
5529 - Safety and efficacy of Ac-225-PSMA-617 in metastatic castration resistant prostate cancer (mCRPC) after failure of Lu-177-PSMA
Presenter: Robert Tauber
Session: Poster Display session 3
Resources:
Abstract